D. Boral Capital Reiterates Buy Rating for ImmunityBio (NASDAQ:IBRX)

D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a report released on Friday,Benzinga reports. They currently have a $30.00 price target on the stock.

Separately, BTIG Research assumed coverage on ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 target price on the stock.

ImmunityBio Price Performance

Shares of IBRX opened at $3.29 on Friday. ImmunityBio has a one year low of $2.28 and a one year high of $10.53. The firm has a market capitalization of $2.29 billion, a P/E ratio of -3.58 and a beta of 0.94. The business has a fifty day moving average of $3.02 and a 200 day moving average of $3.74.

Institutional Investors Weigh In On ImmunityBio

A number of hedge funds have recently made changes to their positions in IBRX. Mirae Asset Global Investments Co. Ltd. increased its stake in ImmunityBio by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after acquiring an additional 4,545 shares during the last quarter. GSA Capital Partners LLP grew its stake in shares of ImmunityBio by 290.3% during the third quarter. GSA Capital Partners LLP now owns 107,985 shares of the company’s stock valued at $402,000 after buying an additional 80,318 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of ImmunityBio during the third quarter valued at approximately $253,000. Charles Schwab Investment Management Inc. grew its stake in shares of ImmunityBio by 2.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,265,981 shares of the company’s stock valued at $4,709,000 after buying an additional 29,665 shares during the last quarter. Finally, Advantage Alpha Capital Partners LP bought a new position in shares of ImmunityBio during the third quarter valued at approximately $257,000. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.